Triazavirin, 250 mg capsules 20 pcs

Antiviral agent.

ATX code: J05AX.

Pharmacological properties

Pharmacodynamics

The active substance of the drug TRIAZAVIRIN

sup>® – riamilovir is a synthetic analog of purine nucleoside bases (guanine) with expressed antiviral action. It has a broad spectrum of antiviral activity against RNA-containing viruses.

The basic mechanism of action of the preparation TRIAZAVIRIN ^® is inhibition of synthesis of viral RNA and replication of genomic fragments.

Pharmacokinetics

After oral administration, it is rapidly absorbed in the gastrointestinal tract. Maximum concentration (C_max) is reached on average in 1-1.5 h. C_max with the recommended dosing regimen is on average 4.8 µg/ml. Blood AUC (area under the pharmacokinetic curve “concentration – time”) is 12.8 µg/h*ml. The elimination half-life (T_1/2) is 1-1.5 h. 15 to 45% of riamilovir is excreted unchanged by the kidneys. The average value of estimated clearance is 246 ml/min.

Indications

Active ingredient

Composition

1 capsule contains:

The active substance: Riamilovir (TRIAZAVIRIN®) – 250 mg,

Excipients: Calcium stearate – 2 mg.

The weight of the capsule contents is 252 mg.

Capsule shell composition:

How to take, the dosage

Triazavirin® is taken orally with plenty of drinking water, regardless of meals. The capsule should be swallowed whole; it is not recommended to chew, crush the capsule.

The drug should be started not later than the 2nd day from the beginning of the disease (manifestation of clinical symptoms of influenza and other acute respiratory viral infections).

Recommended dose:

in influenza and other acute respiratory viral infections: On 1 capsule (250 mg)
3 times daily for 5 consecutive days.

Maximal single dose: 1 capsule (250 mg). Maximum daily dose: 3 capsules (750 mg).

If for 5 days there is no improvement or worsening of symptoms or if new symptoms develop, you should talk to your doctor. Use only according to the indication, route of administration, and dosage listed in the directions.

Interaction

Special Instructions

The drug TRIAZAVIRIN® contains the dyes sunset yellow (E110) and azorubin (E122), which may cause allergic reactions.

Influence on driving, operating machinery

Have not been studied, but based on the spectrum of adverse reactions, no effect on these activities is expected.

Synopsis

Contraindications

Side effects

Disorders of the blood and lymphatic system: increased number of eosinophils in the blood.

Disorders of the immune system: allergic reactions (rash).

Nervous system disorders: headache.

Gastrointestinal tract disorders: dyspeptic phenomena (nausea, vomiting, bloating, pasty stools, flatulence, heartburn, abdominal pain, diarrhea, dry mouth).

Renal and urinary tract disorders: increase in urine red blood cells, white blood cells, squamous epithelium, presence of bacteria in the urine.

Laboratory and instrumental findings: Elevated plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels.

General disorders and reactions at the site of administration: Sweakness.

If you experience or worsen the side effects listed in the instructions, or if you notice any other side effects not listed in the instructions, tell your doctor.

Overdose

Symptoms:nausea, vomiting, dyspeptic disorders, stomach pain.

Treatment:symptomatic therapy. If these symptoms occur, it is necessary to stop taking the drug and consult a physician.

Treatment:Symptomatic therapy.

Pregnancy use